The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

Motokazu Kato1 Chest Disease Clinical and Research Institute, Kishiwada City Hospital, Kishiwada, Japan

https://orcid.org/0000-0003-0411-8703

Keisuke Tomii2 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan

https://orcid.org/0000-0002-3524-6217

Kenichi Hashimoto3 Evidence Generation Department, GlaxoSmithKline K.K., Tokyo, Japan

Yasuko Nezu3 Evidence Generation Department, GlaxoSmithKline K.K., Tokyo, JapanCorrespondence[email protected]

Takeo Ishii4 MA Respiratory Department, GlaxoSmithKline K.K., Tokyo, Japan

C Elaine Jones5 Development, R&D, GlaxoSmithKline, Research Triangle Park, NC, USA

Sally Kilbride6 Biostatistics, GlaxoSmithKline, Uxbridge, Middlesex, UK

Annette S Gross7 Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Sydney, Australia

Christine S Clifton7 Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Sydney, Australia

David A Lipson8 Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA;9 Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

https://orcid.org/0000-0001-6732-4593

show all

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date